SXTC
China Sxt Pharmaceuticals In
NASDAQ · Pharmaceuticals
$3.00
+0.18 (+6.38%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 1.03M | 998.7K | 833.6K |
| Net Income | 146.2K | 158.4K | 135.2K |
| EPS | — | — | — |
| Profit Margin | 14.1% | 15.9% | 16.2% |
| Rev Growth | +22.2% | +6.7% | -0.5% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 1.44M | 1.27M | 1.32M |
| Total Equity | 1.87M | 1.77M | 1.97M |
| D/E Ratio | 0.77 | 0.71 | 0.67 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 286.0K | 317.7K | 242.4K |
| Free Cash Flow | 189.2K | 143.5K | 109.6K |